company background image
4151

Kyowa Kirin TSE:4151 Stock Report

Last Price

JP¥3.15k

Market Cap

JP¥1.7t

7D

-0.2%

1Y

-9.0%

Updated

08 Aug, 2022

Data

Company Financials +
4151 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance5/6
Financial Health6/6
Dividends4/6

4151 Stock Overview

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide.

Kyowa Kirin Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kyowa Kirin
Historical stock prices
Current Share PriceJP¥3,150.00
52 Week HighJP¥4,240.00
52 Week LowJP¥2,604.00
Beta0.27
1 Month Change0.64%
3 Month Change19.82%
1 Year Change-8.96%
3 Year Change72.60%
5 Year Change63.98%
Change since IPO138.64%

Recent News & Updates

Shareholder Returns

4151JP PharmaceuticalsJP Market
7D-0.2%-2.1%0.5%
1Y-9.0%6.0%-0.09%

Return vs Industry: 4151 underperformed the JP Pharmaceuticals industry which returned 6% over the past year.

Return vs Market: 4151 underperformed the JP Market which returned -0.1% over the past year.

Price Volatility

Is 4151's price volatile compared to industry and market?
4151 volatility
4151 Average Weekly Movement3.7%
Pharmaceuticals Industry Average Movement4.1%
Market Average Movement3.9%
10% most volatile stocks in JP Market8.1%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 4151 is not significantly more volatile than the rest of JP stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 4151's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19495,752Masashi Miyamotohttps://www.kyowakirin.com

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics agent.

Kyowa Kirin Fundamentals Summary

How do Kyowa Kirin's earnings and revenue compare to its market cap?
4151 fundamental statistics
Market CapJP¥1.68t
Earnings (TTM)JP¥62.29b
Revenue (TTM)JP¥372.50b

27.2x

P/E Ratio

4.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
4151 income statement (TTM)
RevenueJP¥372.50b
Cost of RevenueJP¥89.98b
Gross ProfitJP¥282.52b
Other ExpensesJP¥220.22b
EarningsJP¥62.29b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 04, 2022

Earnings per share (EPS)115.90
Gross Margin75.84%
Net Profit Margin16.72%
Debt/Equity Ratio0.0%

How did 4151 perform over the long term?

See historical performance and comparison

Dividends

1.5%

Current Dividend Yield

41%

Payout Ratio

Does 4151 pay a reliable dividends?

See 4151 dividend history and benchmarks
When do you need to buy 4151 by to receive an upcoming dividend?
Kyowa Kirin dividend dates
Ex Dividend DateDec 29 2022
Dividend Pay DateMar 28 2023
Days until Ex dividend143 days
Days until Dividend pay date232 days

Does 4151 pay a reliable dividends?

See 4151 dividend history and benchmarks
We’ve recently updated our valuation analysis.

Valuation

Is 4151 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4151?

Other financial metrics that can be useful for relative valuation.

4151 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.6x
Enterprise Value/EBITDA15.3x
PEG Ratio2.4x

Price to Earnings Ratio vs Peers

How does 4151's PE Ratio compare to its peers?

4151 PE Ratio vs Peers
The above table shows the PE ratio for 4151 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average28.4x
4523 Eisai
53.5x5.7%JP¥1.7t
4528 Ono Pharmaceutical
19.4x2.9%JP¥1.6t
4507 Shionogi
17.7x1.7%JP¥2.0t
4578 Otsuka Holdings
24.5x3.9%JP¥2.5t
4151 Kyowa Kirin
27.2x11.3%JP¥1.7t

Price-To-Earnings vs Peers: 4151 is good value based on its Price-To-Earnings Ratio (27.2x) compared to the peer average (28.4x).


Price to Earnings Ratio vs Industry

How does 4151's PE Ratio compare vs other companies in the JP Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 4151 is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the JP Pharmaceuticals industry average (18.1x)


Price to Earnings Ratio vs Fair Ratio

What is 4151's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4151 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.2x
Fair PE Ratio25x

Price-To-Earnings vs Fair Ratio: 4151 is expensive based on its Price-To-Earnings Ratio (27.2x) compared to the estimated Fair Price-To-Earnings Ratio (25x).


Share Price vs Fair Value

What is the Fair Price of 4151 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4151 (¥3150) is trading below our estimate of fair value (¥4620.8)

Significantly Below Fair Value: 4151 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Future Growth

How is Kyowa Kirin forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


11.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4151's forecast earnings growth (11.3% per year) is above the savings rate (0.04%).

Earnings vs Market: 4151's earnings (11.3% per year) are forecast to grow faster than the JP market (8.7% per year).

High Growth Earnings: 4151's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4151's revenue (5.4% per year) is forecast to grow faster than the JP market (4.4% per year).

High Growth Revenue: 4151's revenue (5.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 4151's Return on Equity is forecast to be low in 3 years time (8.9%).


Discover growth companies

Past Performance

How has Kyowa Kirin performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


5.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 4151 has high quality earnings.

Growing Profit Margin: 4151's current net profit margins (16.7%) are higher than last year (13.6%).


Past Earnings Growth Analysis

Earnings Trend: 4151's earnings have grown by 5.4% per year over the past 5 years.

Accelerating Growth: 4151's earnings growth over the past year (40.6%) exceeds its 5-year average (5.4% per year).

Earnings vs Industry: 4151 earnings growth over the past year (40.6%) exceeded the Pharmaceuticals industry 17.2%.


Return on Equity

High ROE: 4151's Return on Equity (8.1%) is considered low.


Discover strong past performing companies

Financial Health

How is Kyowa Kirin's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 4151's short term assets (¥523.3B) exceed its short term liabilities (¥103.5B).

Long Term Liabilities: 4151's short term assets (¥523.3B) exceed its long term liabilities (¥70.9B).


Debt to Equity History and Analysis

Debt Level: 4151 is debt free.

Reducing Debt: 4151 has no debt compared to 5 years ago when its debt to equity ratio was 0.9%.

Debt Coverage: 4151 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 4151 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Kyowa Kirin current dividend yield, its reliability and sustainability?

Dividend Score

4/6

Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


1.52%

Current Dividend Yield

Upcoming Dividend Payment

TodayAug 08 2022Ex Dividend DateDec 29 2022Dividend Pay DateMar 28 202389 days from Ex DividendBuy in the next 143 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 4151's dividend (1.52%) isn’t notable compared to the bottom 25% of dividend payers in the JP market (1.63%).

High Dividend: 4151's dividend (1.52%) is low compared to the top 25% of dividend payers in the JP market (3.62%).


Stability and Growth of Payments

Stable Dividend: 4151's dividends per share have been stable in the past 10 years.

Growing Dividend: 4151's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (40.5%), 4151's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (40.2%), 4151's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Masashi Miyamoto (63 yo)

4.42yrs

Tenure

Mr. Masashi Miyamoto Ph D., serves as Representative Director at Kyowa Kirin Co., Ltd. He serves as President of Kyowa Hakko Kirin Co., Ltd since March 2018, served as a Chief Operating Officer since March...


Leadership Team

Experienced Management: 4151's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: 4151's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Kyowa Kirin Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Kyowa Kirin Co., Ltd.
  • Ticker: 4151
  • Exchange: TSE
  • Founded: 1949
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: JP¥1.680t
  • Shares outstanding: 537.47m
  • Website: https://www.kyowakirin.com

Number of Employees


Location

  • Kyowa Kirin Co., Ltd.
  • Otemachi Financial City Grand Cube
  • 1-9-2, Otemachi
  • Tokyo
  • 100-0004
  • Japan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/08 00:00
End of Day Share Price2022/08/08 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.